. Author manuscript; available in PMC: 2016 Feb 17.

Published in final edited form as: Biol Blood Marrow Transplant. 2015 Sep 30;21(12):2039–2051. doi: 10.1016/j.bbmt.2015.09.016

Table 2.

Results of Phase III Trials Comparing Two to Three Drug Combinations in Patients with Myeloma Failing One to Three Prior Therapies

Ref	ORR (CR)	PFS/OS	Comments
[28]	VTD 88% (28%) TD 72% (13%)	19.8/NS 13.8/NS	First relapse after autologous
[29]	KRD 87% (31.8%) RD 66.6% (9.3%)	26.3/NR 17.6/NR	1 to 3 prior therapies
[30]	Pano Bor Dex 60.7% (NS) Bor Dex 54.6% (NS)	11.9/NS 8.08/NS	1 to 3 prior therapies
[31]	Rev Dex Rev Dex Elo	14.9/NS 19.4/NS	1 to 3 prior therapies

TD indicates thalidomide, dexamethasone; RD, lenalidomide, dexamethasone; Pano Bor Dex, panobinostat, bortezomib, dexamethasone; Bor Dex, bortezomib, dexamethasone; Rev Dex, lenalidomide, dexamethasone.